[1]
Cady R, Schreiber C. Sumatriptan: update and review. Expert opinion on pharmacotherapy. 2006 Aug:7(11):1503-14
[PubMed PMID: 16859433]
Level 3 (low-level) evidence
[2]
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. Journal of pain research. 2018:11():515-526. doi: 10.2147/JPR.S132833. Epub 2018 Mar 8
[PubMed PMID: 29563831]
[3]
Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. SpringerPlus. 2016:5():637. doi: 10.1186/s40064-016-2211-8. Epub 2016 May 17
[PubMed PMID: 27330903]
Level 3 (low-level) evidence
[4]
Eiland LS, Hunt MO. The use of triptans for pediatric migraines. Paediatric drugs. 2010 Dec 1:12(6):379-89. doi: 10.2165/11532860-000000000-00000. Epub
[PubMed PMID: 21028917]
[5]
McKeage K. Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older. Paediatric drugs. 2016 Feb:18(1):75-81. doi: 10.1007/s40272-015-0160-2. Epub
[PubMed PMID: 26747634]
[7]
Belvís R, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent patents on CNS drug discovery. 2009 Jan:4(1):70-81
[PubMed PMID: 19149716]
[8]
Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS drugs. 2008:22(10):877-86
[PubMed PMID: 18788838]
Level 1 (high-level) evidence
[9]
Venkatesan T, Levinthal DJ, Tarbell SE, Jaradeh SS, Hasler WL, Issenman RM, Adams KA, Sarosiek I, Stave CD, Sharaf RN, Sultan S, Li BUK. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterology and motility. 2019 Jun:31 Suppl 2(Suppl 2):e13604. doi: 10.1111/nmo.13604. Epub
[PubMed PMID: 31241819]
[10]
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Archives of neurology. 2002 Jul:59(7):1084-8
[PubMed PMID: 12117355]
[11]
Soldin OP, Dahlin J, O'Mara DM. Triptans in pregnancy. Therapeutic drug monitoring. 2008 Feb:30(1):5-9. doi: 10.1097/FTD.0b013e318162c89b. Epub
[PubMed PMID: 18223456]
[12]
Pöstges T, Lehr M. Metabolism of sumatriptan revisited. Pharmacology research & perspectives. 2023 Feb:11(1):e01051. doi: 10.1002/prp2.1051. Epub
[PubMed PMID: 36655303]
Level 3 (low-level) evidence
[13]
Masuo Y, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y. Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans. Pharmaceutical research. 2017 Jun:34(6):1233-1243. doi: 10.1007/s11095-017-2140-4. Epub 2017 Mar 30
[PubMed PMID: 28361200]
[14]
Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, Martelletti P. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Therapeutic advances in neurological disorders. 2016 Sep:9(5):414-23. doi: 10.1177/1756285616650619. Epub 2016 Jun 3
[PubMed PMID: 27582896]
Level 3 (low-level) evidence
[15]
McEnroe JD, Fleishaker JC. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clinical pharmacokinetics. 2005:44(3):237-46
[PubMed PMID: 15762767]
[16]
Karjalainen MJ, Neuvonen PJ, Backman JT. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic & clinical pharmacology & toxicology. 2008 Aug:103(2):157-65. doi: 10.1111/j.1742-7843.2008.00252.x. Epub
[PubMed PMID: 18816299]
[18]
Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S. Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects. Drug design, development and therapy. 2018:12():331-337. doi: 10.2147/DDDT.S149119. Epub 2018 Feb 19
[PubMed PMID: 29497279]
[19]
Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert opinion on pharmacotherapy. 2000 Mar:1(3):391-404
[PubMed PMID: 11249525]
Level 3 (low-level) evidence
[20]
Láinez MJ, García-Casado A, Gascón F. Optimal management of severe nausea and vomiting in migraine: improving patient outcomes. Patient related outcome measures. 2013 Oct 11:4():61-73. doi: 10.2147/PROM.S31392. Epub 2013 Oct 11
[PubMed PMID: 24143125]
[21]
Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs. 2003:63(21):2285-305
[PubMed PMID: 14524731]
Level 3 (low-level) evidence
[22]
Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. European journal of neurology. 2004 Oct:11(10):671-7
[PubMed PMID: 15469451]
[23]
Sinclair AJ, Sturrock A, Davies B, Matharu M. Headache management: pharmacological approaches. Practical neurology. 2015 Dec:15(6):411-23. doi: 10.1136/practneurol-2015-001167. Epub 2015 Jul 3
[PubMed PMID: 26141299]
[24]
Krymchantowski AV, Jevoux Cda C. The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migraine - a review. Recent patents on CNS drug discovery. 2007 Jun:2(2):141-4
[PubMed PMID: 18221225]
[25]
Aurora SK, Papapetropoulos S, Kori SH, Kedar A, Abell TL. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications. Cephalalgia : an international journal of headache. 2013 Apr:33(6):408-15. doi: 10.1177/0333102412473371. Epub 2013 Mar 5
[PubMed PMID: 23463252]
[26]
Lipton RB, Pascual J, Goadsby PJ, Massiou H, McCarroll KA, Vandormael K, Jiang K, Lines CR. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache. 2001 Sep:41(8):754-63
[PubMed PMID: 11576198]
[27]
Sullivan E, Bushnell C. Management of menstrual migraine: a review of current abortive and prophylactic therapies. Current pain and headache reports. 2010 Oct:14(5):376-84. doi: 10.1007/s11916-010-0138-2. Epub
[PubMed PMID: 20697846]
[28]
Gelfand AA, Goadsby PJ. A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room. The Neurohospitalist. 2012 Apr 1:2(2):51-59
[PubMed PMID: 23936605]
[29]
Cady RK, Farmer K. Managing migraine by patient profile: role of frovatriptan. Patient preference and adherence. 2016:10():501-10. doi: 10.2147/PPA.S85795. Epub 2016 Apr 5
[PubMed PMID: 27103792]
[30]
Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache. 2015 Apr:55(4):490-501. doi: 10.1111/head.12500. Epub 2015 Feb 3
[PubMed PMID: 25644494]
Level 1 (high-level) evidence
[31]
Duong S, Bozzo P, Nordeng H, Einarson A. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Canadian family physician Medecin de famille canadien. 2010 Jun:56(6):537-9
[PubMed PMID: 20547518]
[32]
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep:108(3):776-89
[PubMed PMID: 11533352]
[33]
Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache. 2014 Jul-Aug:54(7):1158-72. doi: 10.1111/head.12375. Epub 2014 May 7
[PubMed PMID: 24805878]
[34]
Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. Basic & clinical pharmacology & toxicology. 2021 Jun:128(6):795-804. doi: 10.1111/bcpt.13579. Epub 2021 Mar 26
[PubMed PMID: 33730376]
[35]
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019 Sep 10:93(11):487-499. doi: 10.1212/WNL.0000000000008095. Epub 2019 Aug 14
[PubMed PMID: 31413171]
Level 1 (high-level) evidence
[36]
Riggins N, Ehrlich A. Episodic Migraine and Older Adults. Current pain and headache reports. 2022 Apr:26(4):331-335. doi: 10.1007/s11916-022-01029-7. Epub 2022 Apr 6
[PubMed PMID: 35384586]
[37]
González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert opinion on drug metabolism & toxicology. 2018 Jan:14(1):25-41. doi: 10.1080/17425255.2018.1416097. Epub 2017 Dec 15
[PubMed PMID: 29226741]
Level 3 (low-level) evidence
[38]
Fox AW. Comparative tolerability of oral 5-HT1B/1D agonists. Headache. 2000 Jul-Aug:40(7):521-7
[PubMed PMID: 10940090]
Level 2 (mid-level) evidence
[39]
Zormpas S, Matsou A, Antunes DM, Panos C. Sumatriptan dose increase-induced acute angle closure glaucoma in chronic migraine sufferer. Drug and therapeutics bulletin. 2022 Aug:60(8):125-127. doi: 10.1136/dtb.2022.235880rep. Epub 2022 Apr 7
[PubMed PMID: 35393301]
[40]
Fonseka GR, Kurchin A. Case Report: Rizatriptan-Induced Ischemic Colitis. Headache. 2015 Jul-Aug:55(7):1008-9. doi: 10.1111/head.12543. Epub 2015 Apr 17
[PubMed PMID: 25881718]
Level 3 (low-level) evidence
[41]
Alkhatib AA, Gangotena F, Peterson KA. Rizatriptan induced acute on top of chronic ischemic colitis. The American journal of gastroenterology. 2009 Oct:104(10):2643-4. doi: 10.1038/ajg.2009.356. Epub
[PubMed PMID: 19806107]
[42]
Akbar A, Nissan G, Chaudhry P, Rangasamy P, Mudrovich S. Isolated naratriptan-associated ischemic colitis. Proceedings (Baylor University. Medical Center). 2016 Oct:29(4):410-411
[PubMed PMID: 27695179]
[43]
Tin S, Lim W, Umyarova R, Arulthasan M, Daoud M. Unusual Case of Ischemic Colitis Caused by Low-Dose Sumatriptan Therapy in a Generally Healthy Patient After Strenuous Physical Activity. Cureus. 2021 Aug:13(8):e17125. doi: 10.7759/cureus.17125. Epub 2021 Aug 12
[PubMed PMID: 34532167]
Level 3 (low-level) evidence
[44]
Acikel S, Dogan M, Sari M, Kilic H, Akdemir R. Prinzmetal-variant angina in a patient using zolmitriptan and citalopram. The American journal of emergency medicine. 2010 Feb:28(2):257.e3-6. doi: 10.1016/j.ajem.2009.05.021. Epub
[PubMed PMID: 20159412]
[45]
Arora A, Arora S. Spontaneous splenic infarction associated with sumatriptan use. The journal of headache and pain. 2006 Sep:7(4):214-6
[PubMed PMID: 16767537]
[46]
Vijayan N, Peacock JH. Spinal cord infarction during use of zolmitriptan: a case report. Headache. 2000 Jan:40(1):57-60
[PubMed PMID: 10759907]
Level 3 (low-level) evidence
[47]
Novitskaya ES, Cates CA, Bowes OM, Vivian AJ. Triptans and third nerve paresis: a case series of three patients. Eye (London, England). 2017 Mar:31(3):503-505. doi: 10.1038/eye.2016.256. Epub 2016 Nov 18
[PubMed PMID: 27858938]
Level 2 (mid-level) evidence
[48]
Hareem A, Pahlavanzadeh M, Calvo NE, Monjazeb S, Anyanwu C. Case report: An EEG captured case of migralepsy/migraine aura-triggered seizures. Frontiers in neurology. 2022:13():953224. doi: 10.3389/fneur.2022.953224. Epub 2022 Aug 11
[PubMed PMID: 36034309]
Level 3 (low-level) evidence
[49]
Goldberg MR, Sciberras D, De Smet M, Lowry R, Tomasko L, Lee Y, Olah TV, Zhao J, Vyas KP, Halpin R, Kari PH, James I. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. British journal of clinical pharmacology. 2001 Jul:52(1):69-76
[PubMed PMID: 11453892]
[50]
Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache. 2003 Oct:43(9):962-74
[PubMed PMID: 14511273]
[51]
Rolan PE. Drug interactions with triptans : which are clinically significant? CNS drugs. 2012 Nov:26(11):949-57. doi: 10.1007/s40263-012-0002-5. Epub
[PubMed PMID: 23018546]
[52]
Munjal S, Brand-Schieber E, Allenby K, Spierings ELH, Cady RK, Rapoport AM. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. The journal of headache and pain. 2017 Dec:18(1):31. doi: 10.1186/s10194-017-0740-3. Epub 2017 Mar 1
[PubMed PMID: 28251391]
[53]
Hill SE, Kirsten L. Triptan-induced torsades de pointes and ventricular fibrillation cardiac arrest: case report and review of the literature. Current drug safety. 2014:9(3):236-9
[PubMed PMID: 24909575]
Level 3 (low-level) evidence
[54]
Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010 Jun:50(6):1089-99. doi: 10.1111/j.1526-4610.2010.01691.x. Epub
[PubMed PMID: 20618823]
[55]
Demaagd G. The pharmacological management of migraine, part 2: preventative therapy. P & T : a peer-reviewed journal for formulary management. 2008 Aug:33(8):480-7
[PubMed PMID: 19750179]
[56]
Do TP, Remmers A, Schytz HW, Schankin C, Nelson SE, Obermann M, Hansen JM, Sinclair AJ, Gantenbein AR, Schoonman GG. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019 Jan 15:92(3):134-144. doi: 10.1212/WNL.0000000000006697. Epub 2018 Dec 26
[PubMed PMID: 30587518]
[57]
Robblee JV, Butterfield RJ, Kang AM, Smith JH. Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System. Neurology. 2020 Apr 7:94(14):e1460-e1469. doi: 10.1212/WNL.0000000000008685. Epub 2019 Dec 2
[PubMed PMID: 31792093]
[58]
Boisselle C, Guthmann R, Cable K. Clinical inquiry. What clinical clues differentiate migraine from sinus headaches? Pulsatile quality, duration of 4 to 72 hours, unilateral location, nausea or vomiting, and disabling intensity. The Journal of family practice. 2013 Dec:62(12):752-4
[PubMed PMID: 24340338]
Level 2 (mid-level) evidence
[59]
Pero A, Pace A, Dhamoon MS. Triptan medication use among patients with migraine with contraindications in the US. Headache. 2022 Jul:62(7):883-889. doi: 10.1111/head.14327. Epub 2022 Jun 7
[PubMed PMID: 35670141]
[60]
Marmura MJ. Triggers, Protectors, and Predictors in Episodic Migraine. Current pain and headache reports. 2018 Oct 5:22(12):81. doi: 10.1007/s11916-018-0734-0. Epub 2018 Oct 5
[PubMed PMID: 30291562]
[61]
Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005 Feb:45(2):156-62
[PubMed PMID: 15705122]
[62]
Baron EP, Markowitz SY, Lettich A, Hastriter E, Lovell B, Kalidas K, Dodick DW, Schwedt TJ, American Headache Society Headache Fellows Research Consortium. Triptan education and improving knowledge for optimal migraine treatment: an observational study. Headache. 2014 Apr:54(4):686-97. doi: 10.1111/head.12286. Epub 2014 Feb 12
[PubMed PMID: 24520930]
Level 2 (mid-level) evidence
[63]
Diamond M, Cady R. Initiating and optimizing acute therapy for migraine: the role of patient-centered stratified care. The American journal of medicine. 2005 Mar:118 Suppl 1():18S-27S
[PubMed PMID: 15841884]